In coming years, scientists plan to grow human embryos in a lab using high-tech artificial wombs.
Doctors at the Children’s Hospital of Philadelphia are in talks with the U.S. Food and Drug Administration (FDA) to begin testing artificial wombs on human embryos within the next two years, according to Metro. If they’re successful, the research could radically change the way we view pregnancy, childbirth, and perhaps even human evolution.
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a material that can significantly extend the life of batteries and afford them higher capacities, as well.
From smartphones to pacemakers and cars, batteries power much of our world and their importance only continues to grow. There are two particular aspects of batteries that many believe need to improve to meet our future needs. These are the longevity of the battery and also its capacity—how much charge it can store.
The chances are your devices use a type of battery called a lithium-ion battery. But another kind based on sodium rather than lithium may become commonplace soon. Both kinds of battery can store and deliver a large amount of charge, thanks to the way constituent materials pass electrons around. But in both lithium and in sodium batteries, repeated cycles of charging and usage can significantly reduce the storage capacity over time.
University at Buffalo researchers have identified the first human-specific fusion gene—a hybrid of two genes—implicated in Alzheimer’s disease. The finding suggests that a neurotransmitter receptor, previously successful in animal studies but that failed in human trials for Alzheimer’s, might still turn out to be a valuable therapy.
In a paper published in February in Translational Psychiatry, the UB researchers reported that this human fusion gene acts on a receptor for the neurotransmitter acetylcholine, which is involved in memory and learning, and which is reduced in people with Alzheimer’s.
The fusion gene is CHRFAM7A, which is very common in people and has been implicated in many neuropsychiatric disorders, such as schizophrenia and bipolar disease.
MIT professor Sangeeta Bhatia is currently devising a simple urine test that works just like a pregnancy test to detect cancer the moment it starts. In this video, Big Think contributor Susan Hockfield, president emerita of MIT, explains how the new technology works.
A mind-controlled hearing aid that allows the wearer to focus on particular voices has been created by scientists, who say it could transform the ability of those with hearing impairments to cope with noisy environments.
The device mimics the brain’s natural ability to single out and amplify one voice against background conversation. Until now, even the most advanced hearing aids work by boosting all voices at once, which can be experienced as a cacophony of sound for the wearer, especially in crowded environments.
Nima Mesgarani, who led the latest advance at Columbia University in New York, said: “The brain area that processes sound is extraordinarily sensitive and powerful. It can amplify one voice over others, seemingly effortlessly, while today’s hearing aids still pale in comparison.”
In the first large-scale analysis of cancer gene fusions, which result from the merging of two previously separate genes, researchers at the Wellcome Sanger Institute, EMBL-EBI, Open Targets, GSK and their collaborators have used CRISPR to uncover which gene fusions are critical for the growth of cancer cells. The team also identified a new gene fusion that presents a novel drug target for multiple cancers, including brain and ovarian cancers.
The results, published today (16 May) in Nature Communications, give more certainty for the use of specific gene fusions to diagnose and guide the treatment of patients. Researchers suggest existing drugs could be repurposed to treat some people with pancreatic, breast and lung cancers, based on the gene fusions found in their tumours.
Gene fusions, caused by the abnormal joining of two otherwise different genes, play an important role in the development of cancer. They are currently used as diagnostic tools to predict how particular cancer patients will respond to drugs, as well as prognostics, to estimate the outcome for a patient given the best possible care. They are also the targets of some of the latest targeted treatments for cancer.
Greg Autry reviews Robert Zubrin’s new book, The Case for Space. The good doctor knows a lot more than just Mars. The book envisions a bright future for humanity in the solar system and beyond, backed by scientific, engineering and economic analysis from the expert who brought us the Case for Mars.
Earlier this year at the Undoing Aging conference in Berlin, I had the opportunity to listen to a debate between Dr. Vadim Gladyshev of Harvard Medical School and Aubrey de Grey of the SENS Research Foundation. The topic was “Is comprehensive damage repair feasible?”
What followed was a friendly and interesting discussion about the three main approaches that might be applied to aging in order to delay, prevent, or reverse age-related diseases.
An entertaining debate between Vadim Gladyshev — Havard Medical School and Aubrey de Grey — SENS Research Foundation.
undoing-aging.org/…/a-debate-between-vadim-gladyshev-and-au…
____________
